BioLineRx Ltd. (TLV:BLRX)

BioLineRx Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	4.63	3.25	10.44	4.26	10.59	12.99
Short-Term Investments	8.45	17.63	9.13	38.74	40.5	44.15
Cash & Short-Term Investments	13.08	20.88	19.56	42.99	51.08	57.14
Cash Growth	-53.56%	6.72%	-54.50%	-15.83%	-10.59%	152.95%
Accounts Receivable	-	0.05	2.48	0.36	-	-
Other Receivables	0.73	0.41	1.39	0.35	0.72	0.14
Receivables	0.73	0.46	3.86	0.71	0.72	0.14
Inventory	2.17	2.15	3.15	1.95	-	-
Prepaid Expenses	0.38	0.2	0.44	1.05	0.2	0.13
Other Current Assets	-	-	0.09	0.48	-	-
Total Current Assets	16.35	23.68	27.1	47.18	52	57.4
Property, Plant & Equipment	0.8	0.86	1.35	1.89	2.5	2.28
Other Intangible Assets	16.33	16.37	10.45	14.85	21.89	21.7
Total Assets	33.48	40.91	38.91	63.93	76.38	81.39

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4.29	3.49	5.58	10.87	6.97	5.57
Accrued Expenses	-	1.21	3.13	3.27	1.66	1.23
Current Portion of Long-Term Debt	4.48	4.48	4.48	3.15	1.54	2.76
Current Portion of Leases	0.28	0.23	0.52	0.53	0.43	0.17
Current Unearned Revenue	-	-	-	12.96	-	-
Other Current Liabilities	4.63	2.71	1.69	12.02	0.08	0
Total Current Liabilities	13.68	12.12	15.41	42.78	10.68	9.72
Long-Term Debt	2.22	4.46	8.96	6.63	8.63	-
Long-Term Leases	0.96	0.98	1.08	1.29	1.73	1.73
Other Long-Term Liabilities	-	-	-	-	4.51	1.86
Total Liabilities	16.86	17.56	25.45	50.7	25.54	13.3

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	73.78	73.43	38.1	31.36	27.1	21.07
Additional Paid-In Capital	327.93	327.58	353.69	355.48	338.98	339.35
Retained Earnings	-405.63	-401	-399.83	-390.61	-329.99	-305.04
Comprehensive Income & Other	17.7	18.19	21.5	16.99	14.76	12.72
Total Common Equity	13.77	18.2	13.46	13.22	50.84	68.09
Minority Interest	2.85	5.15	-	-	-	-
Shareholders' Equity	16.62	23.35	13.46	13.22	50.84	68.09
Total Liabilities & Equity	33.48	40.91	38.91	63.93	76.38	81.39

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	7.94	10.15	15.04	11.59	12.32	4.65
Net Cash (Debt)	5.14	10.73	4.52	31.4	38.76	52.48
Net Cash Growth	-66.98%	137.20%	-85.60%	-18.98%	-26.15%	252.17%
Net Cash Per Share	0.00	0.00	0.00	0.03	0.05	0.08
Filing Date Shares Outstanding	2,621	2,611	2,233	1,087	922.96	715.16
Total Common Shares Outstanding	2,621	2,611	1,337	1,087	922.96	715.16
Working Capital	2.67	11.56	11.7	4.4	41.32	47.69
Book Value Per Share	0.01	0.01	0.01	0.01	0.06	0.10
Tangible Book Value	-2.56	1.83	3.01	-1.63	28.96	46.38
Tangible Book Value Per Share	-0.00	0.00	0.00	-0.00	0.03	0.06
Machinery	-	2.11	2.29	2.93	2.81	2.66
Leasehold Improvements	-	2.04	2.04	2.04	2.04	2.03

Data Source: S&P Global Market Intelligence Last updated: Aug 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 13, 2026

Data Sources Report a data error